hologic/biotheranostics (bioTheranostics)
90
Structured Review
bioTheranostics
hologic/biotheranostics
Hologic/Biotheranostics, supplied by bioTheranostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotheranostics%2C+a+hologic/biotheranostics++a+hologic/10__1016_slash_j__esmoop__2025__104876-39-0-7
Average 90 stars, based on 1 article reviews
Hologic/Biotheranostics, supplied by bioTheranostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotheranostics%2C+a+hologic/biotheranostics++a+hologic/10__1016_slash_j__esmoop__2025__104876-39-0-7
Average 90 stars, based on 1 article reviews
hologic/biotheranostics - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Diagnostic Assay:Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Schnabel: Financial Interests, Personal, Full or part-time Employment: Biotheranostics, A Hologic Company; Financial Interests, Personal, Stocks/Shares: Biotheranostics, A Hologic Company; Financial Interests, Personal, Officer: Biotheranostics, A Hologic Company; Financial Interests, Personal, Other, Patents: Predicting likelihood of response to combination therapy, Registered United States of America Application no: 14/724,732 Application date: 5/28/2015 Registration No: 10,253,369 Registration date: 4/9/2019; Integration of tumor characteristics with breast cancer index, Pending United States of America Application no: 15/349,915 Application date: 11/11/2016; Predicting breast cancer recurrence; pending united states of america application no: 14/483,108 Application date: 9/10/2014; Post-treatment breast cancer prognosis, pending united states of america application no: 15/298,128 Application date: 10/19/2016; Neuroendocrine tumors, Pending United States of America Application no: 15/656,998 Article Title: Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index Article Snippet: Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Article Title: Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. Article Snippet: Ruth M. O’Regan, MD; Yi Zhang, PhD; Gini F. Fleming, MD; Prudence A. Francis, MD; Roswitha Kammler, BA; Giuseppe Viale, MD; Patrizia Dell’Orto, MD; Istvan Lang, MD, PhD; Meritxell Bellet, MD; Herve R. Bonnefoi, MD; Carlo Tondini, MD; Federica Villa, MD; Antonio Bernardo, MD; Eva M. Ciruelos, MD, PhD; Patrick Neven, MD, PhD; Per Karlsson, MD; Bettina Müller, MD; Wolfram Jochum, MD, PhD; Khalil Zaman, MD, PhD; Silvana Martino, DO; Charles E. Geyer Jr, MD; Katarzyna J. Jerzak, MD, MSc; Nancy E. Davidson, MD; Robert E. Coleman, MBBS, MD; James N. Ingle, MD; Marion T. van Mackelenbergh, MD, PhD; Sherene Loi, MD, PhD; Marco Colleoni, MD; Catherine A. Schnabel, PhD; Kai Treuner, PhD; Meredith M. Regan, ScD Clinical Proteomics:Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Schnabel: Financial Interests, Personal, Full or part-time Employment: Biotheranostics, A Hologic Company; Financial Interests, Personal, Stocks/Shares: Biotheranostics, A Hologic Company; Financial Interests, Personal, Officer: Biotheranostics, A Hologic Company; Financial Interests, Personal, Other, Patents: Predicting likelihood of response to combination therapy, Registered United States of America Application no: 14/724,732 Application date: 5/28/2015 Registration No: 10,253,369 Registration date: 4/9/2019; Integration of tumor characteristics with breast cancer index, Pending United States of America Application no: 15/349,915 Application date: 11/11/2016; Predicting breast cancer recurrence; pending united states of america application no: 14/483,108 Application date: 9/10/2014; Post-treatment breast cancer prognosis, pending united states of america application no: 15/298,128 Application date: 10/19/2016; Neuroendocrine tumors, Pending United States of America Application no: 15/656,998 Article Title: Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index Article Snippet: Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Article Title: Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. Article Snippet: Ruth M. O’Regan, MD; Yi Zhang, PhD; Gini F. Fleming, MD; Prudence A. Francis, MD; Roswitha Kammler, BA; Giuseppe Viale, MD; Patrizia Dell’Orto, MD; Istvan Lang, MD, PhD; Meritxell Bellet, MD; Herve R. Bonnefoi, MD; Carlo Tondini, MD; Federica Villa, MD; Antonio Bernardo, MD; Eva M. Ciruelos, MD, PhD; Patrick Neven, MD, PhD; Per Karlsson, MD; Bettina Müller, MD; Wolfram Jochum, MD, PhD; Khalil Zaman, MD, PhD; Silvana Martino, DO; Charles E. Geyer Jr, MD; Katarzyna J. Jerzak, MD, MSc; Nancy E. Davidson, MD; Robert E. Coleman, MBBS, MD; James N. Ingle, MD; Marion T. van Mackelenbergh, MD, PhD; Sherene Loi, MD, PhD; Marco Colleoni, MD; Catherine A. Schnabel, PhD; Kai Treuner, PhD; Meredith M. Regan, ScD Adjuvant:Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Schnabel: Financial Interests, Personal, Full or part-time Employment: Biotheranostics, A Hologic Company; Financial Interests, Personal, Stocks/Shares: Biotheranostics, A Hologic Company; Financial Interests, Personal, Officer: Biotheranostics, A Hologic Company; Financial Interests, Personal, Other, Patents: Predicting likelihood of response to combination therapy, Registered United States of America Application no: 14/724,732 Application date: 5/28/2015 Registration No: 10,253,369 Registration date: 4/9/2019; Integration of tumor characteristics with breast cancer index, Pending United States of America Application no: 15/349,915 Application date: 11/11/2016; Predicting breast cancer recurrence; pending united states of america application no: 14/483,108 Application date: 9/10/2014; Post-treatment breast cancer prognosis, pending united states of america application no: 15/298,128 Application date: 10/19/2016; Neuroendocrine tumors, Pending United States of America Application no: 15/656,998 Article Title: Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index Article Snippet: Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Article Title: Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. Article Snippet: Ruth M. O’Regan, MD; Yi Zhang, PhD; Gini F. Fleming, MD; Prudence A. Francis, MD; Roswitha Kammler, BA; Giuseppe Viale, MD; Patrizia Dell’Orto, MD; Istvan Lang, MD, PhD; Meritxell Bellet, MD; Herve R. Bonnefoi, MD; Carlo Tondini, MD; Federica Villa, MD; Antonio Bernardo, MD; Eva M. Ciruelos, MD, PhD; Patrick Neven, MD, PhD; Per Karlsson, MD; Bettina Müller, MD; Wolfram Jochum, MD, PhD; Khalil Zaman, MD, PhD; Silvana Martino, DO; Charles E. Geyer Jr, MD; Katarzyna J. Jerzak, MD, MSc; Nancy E. Davidson, MD; Robert E. Coleman, MBBS, MD; James N. Ingle, MD; Marion T. van Mackelenbergh, MD, PhD; Sherene Loi, MD, PhD; Marco Colleoni, MD; Catherine A. Schnabel, PhD; Kai Treuner, PhD; Meredith M. Regan, ScD Biomarker Discovery:Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Schnabel: Financial Interests, Personal, Full or part-time Employment: Biotheranostics, A Hologic Company; Financial Interests, Personal, Stocks/Shares: Biotheranostics, A Hologic Company; Financial Interests, Personal, Officer: Biotheranostics, A Hologic Company; Financial Interests, Personal, Other, Patents: Predicting likelihood of response to combination therapy, Registered United States of America Application no: 14/724,732 Application date: 5/28/2015 Registration No: 10,253,369 Registration date: 4/9/2019; Integration of tumor characteristics with breast cancer index, Pending United States of America Application no: 15/349,915 Application date: 11/11/2016; Predicting breast cancer recurrence; pending united states of america application no: 14/483,108 Application date: 9/10/2014; Post-treatment breast cancer prognosis, pending united states of america application no: 15/298,128 Application date: 10/19/2016; Neuroendocrine tumors, Pending United States of America Application no: 15/656,998 Article Title: Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index Article Snippet: Article Title: 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial Article Snippet: Article Title: Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. Article Snippet: Ruth M. O’Regan, MD; Yi Zhang, PhD; Gini F. Fleming, MD; Prudence A. Francis, MD; Roswitha Kammler, BA; Giuseppe Viale, MD; Patrizia Dell’Orto, MD; Istvan Lang, MD, PhD; Meritxell Bellet, MD; Herve R. Bonnefoi, MD; Carlo Tondini, MD; Federica Villa, MD; Antonio Bernardo, MD; Eva M. Ciruelos, MD, PhD; Patrick Neven, MD, PhD; Per Karlsson, MD; Bettina Müller, MD; Wolfram Jochum, MD, PhD; Khalil Zaman, MD, PhD; Silvana Martino, DO; Charles E. Geyer Jr, MD; Katarzyna J. Jerzak, MD, MSc; Nancy E. Davidson, MD; Robert E. Coleman, MBBS, MD; James N. Ingle, MD; Marion T. van Mackelenbergh, MD, PhD; Sherene Loi, MD, PhD; Marco Colleoni, MD; Catherine A. Schnabel, PhD; Kai Treuner, PhD; Meredith M. Regan, ScD |